PLA-695

10/29/2021 - "Administration of BCSCs using clinic therapeutic drugs such as doxorubicin, cisplatin, or tamoxifen combined with Giripladib (an inhibitor of cytoplasmic phospholipase A2) can efficiently eliminate BCSCs and tumorigenesis. "

01/01/2013 - "LLC and A549 tumors treated with a combination of PLA-695 and radiation displayed reduced tumor vasculature. "
01/01/2013 - "In a heterotopic tumor model, the combination of PLA-695 and radiation delayed growth in both LLC and A549 tumors. "
01/01/2013 - "PLA-695 in combination with irradiation (IR) significantly reduced migration and proliferation in endothelial cells (HUVEC & bEND3) and induced cell death and attenuated invasion by tumor cells (LLC &A549). "
01/01/2013 - "Utilizing the cPLA2 specific inhibitor PLA-695, we determined if cPLA2 inhibition radiosensitizes non small cell lung cancer (NSCLC) cells and tumors. "
01/01/2013 - "Cytosolic phospholipaseA2 inhibition with PLA-695 radiosensitizes tumors in lung cancer animal models."

01/01/2013 - "Cytosolic phospholipaseA2 inhibition with PLA-695 radiosensitizes tumors in lung cancer animal models."

01/01/2013 - "Utilizing the cPLA2 specific inhibitor PLA-695, we determined if cPLA2 inhibition radiosensitizes non small cell lung cancer (NSCLC) cells and tumors. "